MERUS NV (MRUS) Fundamental Analysis & Valuation

NASDAQ:MRUS • NL0011606264

Current stock price

90 USD
-6.92 (-7.14%)
At close:
88.97 USD
-1.03 (-1.14%)
After Hours:

This MRUS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MRUS Profitability Analysis

1.1 Basic Checks

  • MRUS had negative earnings in the past year.
  • MRUS had a negative operating cash flow in the past year.
  • In the past 5 years MRUS always reported negative net income.
  • MRUS had a negative operating cash flow in each of the past 5 years.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

  • With a Return On Assets value of -42.15%, MRUS perfoms like the industry average, outperforming 57.74% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of -49.16%, MRUS is in the better half of the industry, outperforming 66.79% of the companies in the same industry.
Industry RankSector Rank
ROA -42.15%
ROE -49.16%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

  • MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MRUS Health Analysis

2.1 Basic Checks

  • MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MRUS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MRUS has been increased compared to 5 years ago.
  • MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • MRUS has an Altman-Z score of 29.22. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
  • MRUS has a Altman-Z score of 29.22. This is amongst the best in the industry. MRUS outperforms 93.21% of its industry peers.
  • There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 29.22
ROIC/WACCN/A
WACC7.43%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • MRUS has a Current Ratio of 7.95. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
  • MRUS has a better Current ratio (7.95) than 74.15% of its industry peers.
  • MRUS has a Quick Ratio of 7.95. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
  • With a decent Quick ratio value of 7.95, MRUS is doing good in the industry, outperforming 74.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.95
Quick Ratio 7.95
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. MRUS Growth Analysis

3.1 Past

  • MRUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -36.92%.
  • Looking at the last year, MRUS shows a very strong growth in Revenue. The Revenue has grown by 57.54%.
  • MRUS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.03% yearly.
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%

3.2 Future

  • MRUS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 26.66% yearly.
  • The Revenue is expected to grow by 89.98% on average over the next years. This is a very strong growth
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. MRUS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MRUS. In the last year negative earnings were reported.
  • Also next year MRUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as MRUS's earnings are expected to decrease with -11.15% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MRUS Dividend Analysis

5.1 Amount

  • MRUS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MRUS Fundamentals: All Metrics, Ratios and Statistics

MERUS NV

NASDAQ:MRUS (12/29/2025, 8:07:25 PM)

After market: 88.97 -1.03 (-1.14%)

90

-6.92 (-7.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength36.49
Industry Growth78
Earnings (Last)10-31
Earnings (Next)02-25
Inst Owners91.04%
Inst Owner Change-0.03%
Ins Owners0.22%
Ins Owner Change-2.86%
Market Cap6.83B
Revenue(TTM)56.61M
Net Income(TTM)-381.00M
Analysts70.43
Price Target99.48 (10.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-36.37%
Min EPS beat(2)-83.38%
Max EPS beat(2)10.64%
EPS beat(4)2
Avg EPS beat(4)-12.3%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-15.65%
EPS beat(12)6
Avg EPS beat(12)-12.87%
EPS beat(16)10
Avg EPS beat(16)1.31%
Revenue beat(2)1
Avg Revenue beat(2)-0.47%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)36.26%
Revenue beat(4)2
Avg Revenue beat(4)55.58%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)27.5%
Revenue beat(12)6
Avg Revenue beat(12)19.96%
Revenue beat(16)9
Avg Revenue beat(16)16.38%
PT rev (1m)0%
PT rev (3m)5.25%
EPS NQ rev (1m)1.35%
EPS NQ rev (3m)5.18%
EPS NY rev (1m)0.77%
EPS NY rev (3m)4.56%
Revenue NQ rev (1m)-2.85%
Revenue NQ rev (3m)-4.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)6%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 120.6
P/FCF N/A
P/OCF N/A
P/B 8.81
P/tB 8.83
EV/EBITDA N/A
EPS(TTM)-5.34
EYN/A
EPS(NY)-5.41
Fwd EYN/A
FCF(TTM)-4.2
FCFYN/A
OCF(TTM)-4.19
OCFYN/A
SpS0.75
BVpS10.22
TBVpS10.19
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -42.15%
ROE -49.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.97%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.95
Quick Ratio 7.95
Altman-Z 29.22
F-Score4
WACC7.43%
ROIC/WACCN/A
Cap/Depr(3y)275.81%
Cap/Depr(5y)194.96%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-36.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.7%
EPS Next Y-75.87%
EPS Next 2Y-27.83%
EPS Next 3Y-11.15%
EPS Next 5Y26.66%
Revenue 1Y (TTM)57.54%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%3.21%
Revenue Next Year43.37%
Revenue Next 2Y17.82%
Revenue Next 3Y66.5%
Revenue Next 5Y89.98%
EBIT growth 1Y-60.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.55%
EBIT Next 3Y-2.47%
EBIT Next 5YN/A
FCF growth 1Y-123.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-133.19%
OCF growth 3YN/A
OCF growth 5YN/A

MERUS NV / MRUS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MERUS NV?

ChartMill assigns a fundamental rating of 4 / 10 to MRUS.


What is the valuation status for MRUS stock?

ChartMill assigns a valuation rating of 0 / 10 to MERUS NV (MRUS). This can be considered as Overvalued.


What is the profitability of MRUS stock?

MERUS NV (MRUS) has a profitability rating of 1 / 10.


What is the financial health of MERUS NV (MRUS) stock?

The financial health rating of MERUS NV (MRUS) is 8 / 10.